Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.
Looking for a particular Fluicell AB employee's phone or email?
Fluicell AB Questions
The Fluicell AB annual revenue was $1 million in 2026.
Carolina Trkulja is the CEO of Fluicell AB.
8 people are employed at Fluicell AB.
The NAICS codes for Fluicell AB are [54, 541714, 541, 54171, 5417].
The SIC codes for Fluicell AB are [873, 87].
Top Fluicell AB Employees
-
Carolina Trkulja
CEO at Fluicell AB
Gothenburg, SE1 -
Gavin Jeffries
Chief Technology Officer at Fluicell AB
Gothenburg, SE53 -
2
-
Avadhesh Singh
Lead Scientist at Fluicell AB
Gothenburg, SE2 -
Renooza Nizam
Laboratory Assistant at Fluicell AB
Gothenburg, SE
Related Companies
